Fig. 3: Overall survival and cumulative incidence of relapse by pre-transplant MRD status in patients who received PTCy-based compared to tacrolimus/sirolimus-based GVHD prophylaxis. | Bone Marrow Transplantation

Fig. 3: Overall survival and cumulative incidence of relapse by pre-transplant MRD status in patients who received PTCy-based compared to tacrolimus/sirolimus-based GVHD prophylaxis.

From: Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease

Fig. 3

a OS in MRD− and MRD+ patients who received PTCy-based GVHD prophylaxis. b OS in MRD− and MRD+ patients who received tacrolimus/sirolimus-based GVHD prophylaxis. c CIR in MRD− and MRD+ patients who received PTCy-based GVHD prophylaxis. d CIR in MRD− and MRD+ patients who received tacrolimus/sirolimus-based GVHD prophylaxis.

Back to article page